iSchemaView, Inc.

Rapid AI develops deep clinical artificial intelligence software for medical imaging analysis, specializing in neurovascular, cardiac & vascular, and radiology applications. The company's Rapid Enterprise™ Platform delivers FDA-cleared clinical decision support modules that enhance diagnostic confidence and streamline workflows across 2,500+ hospitals in 100+ countries. Core offerings include AI-driven triage, localization, quantification, characterization, and 3D visualization capabilities for stroke (hemorrhagic and ischemic), aneurysm, pulmonary embolism, and general radiology cases. The mobile app enables real-time alerts, case collaboration, DICOM viewer integration, EMR connectivity, and procedural workflow initiation. Rapid AI products include Lumina 3D (advanced 3D rendering and analysis, named to TIME's Best Inventions 2025), Navigator Pro (radiology workflow prioritization), and Rapid Insights (custom analytics). The company has received 30 FDA-cleared modules and maintains extensive clinical validation: 700+ peer-reviewed publications, 25+ clinical trials, 11 NEJM publications, and 17.5 mean impact factor. Processing 20,000+ daily scans, Rapid AI serves stroke centers, trauma departments, cardiac services, and life sciences organizations conducting clinical trials. The platform supports interoperability with third-party healthcare systems and EMRs, enabling cross-disciplinary deployment of AI decision support.